


Curriculum Vitae

Name	Vivek Subbiah	
Current Position & Affiliation	Associate Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX	
Country	USA	
Educational Background		

Degree-Granting Education

Sri Ramachandra Medical College & Research Institute, Chennai, India, MBBS, 2002, Bachelor of Medicine and Bachelor of Surgery

Postgraduate Training

Clinical Internship, Medicine and Surgery, Sri Ramachandra Medical College & Research Institute, Chennai, India, Dr. K.V. Somasundaram, 2001-2002

Visiting Scholar, Emergency Medicine, Stanford University Medical Center, Division of Emergency Medicine, Palo Alto, CA, Dr. Swaminatha Mahadevan, 2003-2003

Clinical Internship, Internal Medicine and Pediatrics Combined Internship, Case Western Reserve University School of Medicine (Metrohealth Medical Center), Cleveland, OH, Dr. David Mansour, 7/2004-6/2005

Clinical Residency, Internal Medicine and Pediatrics Combined Residency, Case Western Reserve University School of Medicine, Cleveland, OH, Dr. David Mansour, 7/2005-6/2008

Clinical Fellowship, Pediatric Hematology/Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, Dr. Susan S. Kelly, 7/2008-6/2011

Research Fellowship, Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, Dr. Razelle Kurzrock, 10/2009-6/2011

Clinical Fellowship, Adult Medical Oncology Fellowship, The University of Texas MD Anderson Cancer Center, Houston, TX, Dr. Robert Wolff, 7/2011-6/2012

Heart of Leadership Program, The University of Texas MD Anderson Cancer

Center, Houston, TX, 2013-2014

Heart of Leadership Program 2, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017-2018

LEAD Program, Leadership Developmental Program, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019-2020

Professional Experience

Academic Appointments

Assistant Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012-2018

Assistant Professor, Department of Pediatrics Patient Care, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, 2014-2018

Assistant Professor, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, 2014-2018

Associate Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2018-present

Associate Professor, Department of Pediatrics Patient Care, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, 2018-present

Associate Professor, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, 2018-present

Professional Organizations

Board Certification

Education Commission for Foreign Medical Graduates (ECFMG), 2004

Diplomate of American Board of Internal Medicine (ABIM)., 2008-2018

Diplomate of American Board of Pediatrics (ABP), 2011-2021

American Board of Medical Oncology, 2014-2024

Main Scientific Publications

01. Sen S, Kato S, Agarwal R, Piha-Paul S, Hess K, Karp D, Janku F, Fu S, Naing A, Pant S, Falchook G, Tang C, Wu X, Ye Y, Tsimberidou A, Subbiah V, Kurzrock R, Byers L, Westin S, Lim J, Bean S, Bass A, Nguyen L, Meric-Bernstam F, Hong D. Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers. *Br J Cancer* 118(11):1419-1424, 5/2018. e-Pub 4/2018. PMID: PMC5988803.
02. Subbiah V, Rodon J, Yap TA. Precision oncology: East meets West. *Int J Cancer* 142(9):1734-1737, 5/2018. e-Pub 1/2018. PMID: 29243227.
03. Ghosh P, Chandler AG, Hobbs BP, Sun J, Rong J, Hong D, Subbiah V, Janku F, Naing A, Hwu WJ, Ng CS. Quantification of the Effect of Shuttling on Computed Tomography Perfusion Parameters by Investigation of Aortic Inputs on Different Table Positions From Shuttle-Mode Scans of Lung and Liver Tumors. *J Comput Assist Tomogr* 42(3):357-364, May/Jun, 5/2018. PMID: 29189398.
04. Maymani H, Hess K, Groisberg R, Hong DS, Naing A, Piha-Paul S, Janku F, Fu S, Tsimberidou AM, Pant S, Karp D, Liu S, Sun M, Heymach J, Simon G, Meric-Bernstam F, Subbiah V. Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials. *Lung Cancer* 120:137-141, 6/2018. e-Pub 4/2018. PMID: PMC6204221.
05. Groisberg R, Hong DS, Roszik J, Janku F, Tsimberidou AM, Javle M, Meric-Bernstam F, Subbiah V. Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers. *Mol Cancer Ther* 17(7):1595-1601, 7/2018. e-Pub 4/2018. PMID: 29654067.
06. Parseghian CM, Patnana M, Bhosale P, Hess KR, Shih YT, Kim B, Kopetz S, Overman MJ, Varadhachary GR, Javle M, Naing A, Piha-Paul S, Hong D, Le H, Subbiah V, Pant S. Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy. *J Immunother* 41(6):284-291, Jul/Aug, 7/2018. PMID: PMC6028046.
07. Roszik J, Subbiah V. Mining Public Databases for Precision Oncology. *Trends Cancer* 4(7):463-465, 7/2018. e-Pub 5/2018. PMID: 29937043.
08. Subbiah V, Gainor JF, Rahal R, Brubaker JD, Kim JL, Maynard M, Hu W, Cao Q, Sheets MP, Wilson D, Wilson KJ, DiPietro L, Fleming P, Palmer M, Hu MI, Wirth L, Brose MS, Ou SI, Taylor M, Garralda E, Miller S, Wolf B, Lengauer

- C, Guzi T, Evans EK. Precision Targeted Therapy with BLU-667 for RET-Driven Cancers. *Cancer Discov* 8(7):836-849, 7/2018. e-Pub 4/2018. PMID: 29657135.
09. Subbiah V, Murthy R, Hong DS, Prins RM, Hosing C, Hendricks K, Kolli D, Noffsinger L, Brown R, McGuire M, Fu S, Piha-Paul S, Naing A, Conley AP, Benjamin RS, Kaur I, Bosch ML. Cytokines Produced by Dendritic Cells Administered Intratumorally Correlate with Clinical Outcome in Patients with Diverse Cancers. *Clin Cancer Res* 24(16):3845-3856, 8/2018. e-Pub 7/2018. PMID: 30018119.
10. Dumbrava EI, Ivan D, Subbiah V. Hypopigmented Skin Lesions After Immunotherapy. *JAMA Oncol* 4(8):1118-1119, 8/2018. PMID: 29801033.
11. Fujii T, Colen RR, Bilen MA, Hess KR, Hajjar J, Suarez-Almazor ME, Alshawa A, Hong DS, Tsimberidou A, Janku F, Gong J, Stephen B, Subbiah V, Piha-Paul SA, Fu S, Sharma P, Mendoza T, Patel A, Thirumurthi S, Sheshadri A, Meric-Bernstam F, Naing A. Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. *Invest New Drugs* 36(4):638-646, 8/2018. e-Pub 11/2017. PMID: PMC5962379.
12. Wang Y, Wang Z, Piha-Paul S, Janku F, Subbiah V, Shi N, Hess K, Broaddus R, Shan B, Naing A, Hong D, Tsimberidou AM, Karp D, Lu C, Papadimitrakopoulou V, Heymach J, Meric-Bernstam F, Fu S. Outcome analysis of Phase I trial patients with metastatic KRAS and/or TP53 mutant non-small cell lung cancer. *Oncotarget* 9(70):33258-33270, 9/2018. e-Pub 9/2018. PMID: PMC6161801.
13. Dembla V, Somaiah N, Barata P, Hess K, Fu S, Janku F, Karp DD, Naing A, Piha-Paul SA, Subbiah V, Tsimberidou AM, Shaw K, Meric-Bernstam F, Hong DS. Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic. *Oncotarget* 9(69):33232-33243, 9/2018. e-Pub 9/2018. PMID: PMC6145698.
14. Kaley T, Touat M, Subbiah V, Hollebecque A, Rodon J, Lockhart AC, Keedy V, Bielle F, Hofheinz RD, Joly F, Blay JY, Chau I, Puzanov I, Raje NS, Wolf J, DeAngelis LM, Makrutzki M, Riehl T, Pitcher B, Baselga J, Hyman DM. BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study. *J Clin Oncol*:JCO2018789990. e-Pub 10/2018. PMID: 30351999.
15. Arudra K, Patel R, Tetzlaff MT, Hymes S, Subbiah V, Meric-Bernstam F, Torres-Cabala C, Aung PP, Nagarajan P, Diab A, Prieto VG, Nelson K, Curry JL. Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor

- receptor inhibitor for the treatment of Wilms tumor. *J Cutan Pathol* 45(10):786-790, 10/2018. e-Pub 8/2018. PMID: 30021048.
16. Subbiah V, Lamhamedi-Cherradi SE, Cuglievan B, Menegaz BA, Camacho P, Huh W, Ramamoorthy V, Anderson PM, Pollock RE, Lev DC, Qiao W, McAleer MF, Benjamin RS, Patel S, Herzog CE, Daw NC, Feig BW, Lazar AJ, Hayes-Jordan A, Ludwig JA. Multimodality Treatment of Desmoplastic Small Round Cell Tumor: Chemotherapy and Complete Cytoreductive Surgery Improve Patient Survival. *Clin Cancer Res* 24(19):4865-4873, 10/2018. e-Pub 6/2018. PMCID: PMC6168359.
 17. Subbiah V, Kurzrock R. The Marriage Between Genomics and Immunotherapy: Mismatch Meets Its Match. *Oncologist*. e-Pub 10/2018. PMID: 30352943.
 18. Fountzilias E, Krishnan E, Janku F, Fu S, Karp DD, Naing A, Subbiah V, Hong DS, Piha-Paul SA, Vining DJ, Tsimberidou AM. A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and predominant liver involvement. *Cancer Chemother Pharmacol* 82(5):877-885, 11/2018. e-Pub 9/2018. PMID: 30182147.
 19. Bhatta M, Kato S, Piha-Paul SA, Naing A, Subbiah V, Huang HJ, Karp DD, Tsimberidou AM, Zinner RG, Hwu WJ, Javle M, Patel SP, Hu MI, Varadhachary GR, Conley AP, Ramzanali NM, Holley VR, Kurzrock R, Meric-Bernstam F, Kwang Chae Y, Kim KB, Falchook GS, Janku F. Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients With BRAF-mutated melanoma and other advanced malignancies. *Cancer*. e-Pub 11/2018. PMID: 30383888.
 20. Kato S, Ross JS, Gay L, Dayyani F, Roszik J, Subbiah V, Kurzrock R. Analysis of MDM2 Amplification: Next-Generation Sequencing of Patients With Diverse Malignancies. *JCO Precis Oncol* 2018, 2018. e-Pub 7/2018. PMCID: PMC6106866.
 21. Grinshpun A, Zarbiv Y, Roszik J, Subbiah V, Hubert A. Beyond KRAS: Practical Molecular Targets in Pancreatic Adenocarcinoma. *Case Rep Oncol* 12(1):7-13, Jan-Apr, 1/2019. e-Pub 1/2019. PMCID: PMC6381925.
 22. George GC, Iwuanyanwu EC, Buford AS, Piha-Paul SA, Subbiah V, Fu S, Karp DD, Pant S, Hinojosa CO, Hess KR, Cleeland CS, Bernstam EV, Meric-Bernstam F, Hong DS. Cancer-Related Internet Use and Its Association With

- Patient Decision Making and Trust in Physicians Among Patients in an Early Drug Development Clinic: A Questionnaire-Based Cross-Sectional Observational Study. *J Med Internet Res* 21(3):e10348, 3/2019. e-Pub 3/2019. PMID: PMC6437608.
23. Kairemo K, Wang WL, Subbiah V. Comprehensive molecular imaging of malignant transformation of giant cell tumour of bone reveals diverse disease biology. *BMJ Case Rep* 12(4), 4/2019. e-Pub 4/2019. PMID: 31015231.
24. Conley AP, Wang WL, Livingston JA, Ravi V, Tsai JW, Ali A, Ingram DR, Lowery CD, Roland CL, Somaiah N, Hwu P, Yee C, Subbiah V, Futreal A, Lazar AJ, Patel S, Roszik J. MAGE-A3 is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma. *Cancers (Basel)* 11(5), 5/2019. e-Pub 5/2019. PMID: PMC6562561.
25. Kairemo K, Subbiah V. Molecular imaging of metastatic atrial angiosarcoma with positron emission tomography (PET) tracer 3'-deoxy-3'[(18)F]-fluorothymidine, [(18)F]-FLT imaging and early response evaluation. *BMJ Case Rep* 12(5), 5/2019. e-Pub 5/2019. PMID: 31061188.
26. Doan HQ, Hu MI, Goldstein J, Piha-Paul SA, Subbiah V, Patel AB. Vandetanib photoinduced cutaneous toxicities. *Cutis* 103(5):E24-E29, 5/2019. PMID: 31233590.
27. Subbiah V, Anderson PM, Kairemo K, Hess K, Huh WW, Ravi V, Daw NC, Somaiah N, Ludwig JA, Benjamin RS, Chawla S, Hong DS, Meric-Bernstam F, Ravizzini G, Kleinerman E, Macapinlac H, Rohren E. Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial. *Clin Cancer Res* 25(13):3802-3810, 7/2019. e-Pub 2/2019. PMID: PMC6606382.
28. Subbiah V, Sircar K. Personalizing Precision Oncology: From Light Microscope to Molecular Microscope. *J Natl Compr Canc Netw* 17(7):886-888, 7/2019. PMID: 31319384.
29. Roszik J, Khan A, Conley AP, Livingston JA, Groisberg R, Ravi V, Carmagnani Pestana R, Sen S, Subbiah V. Unique Aberrations in Intimal Sarcoma Identified by Next-Generation Sequencing as Potential Therapy Targets. *Cancers (Basel)* 11(9), 8/2019. e-Pub 8/2019. PMID: PMC6770224.
30. Kurzrock R, Ball DW, Zahurak ML, Nelkin BD, Subbiah V, Ahmed S, O'Connor A, Karunsena E, Parkinson RM, Bishop JA, Ha Y, Sharma R, Gocke CD, Zinner R, Rudek MA, Sherman SI, Azad NS. A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK

Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers. *Clin Cancer Res* 25(18):5475-5484, 9/2019. e-Pub 6/2019. PMID: 31186313.

31. Habra MA, Stephen B, Campbell M, Hess K, Tapia C, Xu M, Rodon Ahnert J, Jimenez C, Lee JE, Perrier ND, Boraddus RR, Pant S, Subbiah V, Hong DS, Zarifa A, Fu S, Karp DD, Meric-Bernstam F, Naing A. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma. *J Immunother Cancer* 7(1):253, 9/2019. e-Pub 9/2019. PMID: PMC6751592.
32. Rich TA, Reckamp KL, Chae YK, Doebele RC, Iams WT, Oh M, Raymond VM, Lanman RB, Riess JW, Stinchcombe TE, Subbiah V, Trevarthen DR, Fairclough S, Yen J, Gauschi O. Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations. *Clin Cancer Res* 25(19):5832-5842, 10/2019. e-Pub 7/2019. PMID: PMC6774853.
33. Adashek JJ, Subbiah IM, Subbiah V. Artificial Intelligence Systems Assisting Oncologists? Resist and Desist or Enlist and Coexist. *Oncologist* 24(10):1291-1293, 10/2019. e-Pub 7/2019. PMID: PMC6795157.
34. Maymani H, Hess K, Groisberg R, Hong DS, Naing A, Piha-Paul S, Janku F, Fu S, Tsimberidou AM, Pant S, Karp D, Liu S, Sun M, Heymach J, Simon G, Meric-Bernstam F, Subbiah V. Corrigendum to "Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials" [*Lung Cancer* 120 (June) (2018) 137-141]. *Lung Cancer* 136:158, 10/2019. e-Pub 8/2019. PMID: 31445783.
35. Maxwell JE, Gule-Monroe MK, Subbiah V, Hu M, Perrier ND, Cabanillas ME, Lee JE, Graham PH, Cote GJ, Busaidy NL, Grubbs EG. Novel use of a CLIA-certified CDKN2C loss assay in sporadic medullary thyroid carcinoma. *Surgery*. e-Pub 10/2019. PMID: 31648931.
36. Welsh JW, Tang C, de Groot P, Naing A, Hess KR, Heymach JV, Papadimitrakopoulou VA, Cushman TR, Subbiah V, Chang JY, Simon GR, Ramapriyan R, Barsoumian HB, Menon H, Cortez MA, Massarelli E, Nguyen Q, Sharma P, Allison JP, Diab A, Verma V, Raju U, Shaaban SG, Dadu R, Cabanillas ME, Wang K, Anderson C, Gomez DR, Hahn S, Komaki R, Hong DS. Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses. *Cancer Immunol Res*. e-Pub 10/2019. PMID: 31658994.

37. Kairemo K, Rohren EM, Anderson PM, Ravizzini G, Rao A, Macapinlac HA, Subbiah V. Development of sodium fluoride PET response criteria for solid tumours (NAFCIST) in a clinical trial of radium-223 in osteosarcoma: from RECIST to PERCIST to NAFCIST. *ESMO Open* 4(1):e000439, 2019. e-Pub 2/2019. PMID: PMC6435244.
38. Kairemo K, Santos EB, Macapinlac HA, Subbiah V. Early Response Assessment to Targeted Therapy Using 3'-deoxy-3'[(18F)]-Fluorothymidine (18F-FLT) PET/CT in Lung Cancer. *Diagnostics (Basel)* 10(1), 1/2020. e-Pub 1/2020. PMID: PMC7169847
39. Dickson D, Johnson J, Bergan R, Owens R, Subbiah V, Kurzrock R. The Master Observational Trial: A New Class of Master Protocol to Advance Precision Medicine. *Cell* 180(1):9-14, 1/2020. PMID: 31951522.
40. Wang Y, Janku F, Piha-Paul S, Hess K, Broaddus R, Liu L, Shi N, Overman M, Kopetz S, Subbiah V, Naing A, Hong D, Tsimberidou AM, Karp D, Yao J, Fu S. Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies. *Sci Rep* 10(1):3080, 2/2020. e-Pub 2/2020. PMID: PMC7033174.
41. Adashek JJ, Leonard A, Roszik J, Menta AK, Genovese G, Subbiah V, Msaouel P. Cancer Genetics and Therapeutic Opportunities in Urologic Practice. *Cancers (Basel)* 12(3), 3/2020. e-Pub 3/2020. PMID: PMC7140104.
42. Adashek JJ, Subbiah IM, Matos I, Garralda E, Menta AK, Ganeshan DM, Subbiah V. Hyperprogression and Immunotherapy: Fact, Fiction, or Alternative Fact? *Trends Cancer* 6(3):181-191, 3/2020. e-Pub 2/2020. PMID: 32101722.
43. Naing A, Meric-Bernstam F, Stephen B, Karp DD, Hajjar J, Rodon Ahnert J, Piha-Paul SA, Colen RR, Jimenez C, Raghav KP, Ferrarotto R, Tu SM, Campbell M, Wang L, Sabir SH, Tapia C, Bernatchez C, Frumovitz M, Tannir N, Ravi V, Khan S, Painter JM, Abonofal A, Gong J, Alshawa A, McQuinn LM, Xu M, Ahmed S, Subbiah V, Hong DS, Pant S, Yap TA, Tsimberidou AM, Dumbreva EEI, Janku F, Fu S, Simon RM, Hess KR, Varadhachary GR, Habra MA. Phase 2 study of pembrolizumab in patients with advanced rare cancers. *J Immunother Cancer* 8(1), 3/2020. PMID: PMC7078933.
44. Anderson PM, Scott J, Parsai S, Zahler S, Worley S, Shrikanthan S, Subbiah V, Murphy E. 223-Radium for metastatic osteosarcoma: combination therapy with other agents and external beam radiotherapy. *ESMO Open* 5(2), 4/2020. PMID: PMC7199915.

45. Subbiah V, Cote GJ. Advances in Targeting RET-Dependent Cancers. *Cancer Discov* 10(4):498-505, 4/2020. e-Pub 2/2020. PMID: PMC7125013.
46. Narayanan S, Lazar Neto F, Tanco K, Lopez G, Liu W, Bruera E, Subbiah V. Cannabidiol (CBD) Oil, Cancer, and Symptom Management: A Google Trends Analysis of Public Interest. *J Altern Complement Med* 26(4):346-348, 4/2020. e-Pub 1/2020. PMID: PMC7153638.
47. Pairawan S, Hess KR, Janku F, Sanchez NS, Mills Shaw KR, Eng C, Damodaran S, Javle M, Kaseb AO, Hong DS, Subbiah V, Fu S, Fogelman DR, Raymond VM, Lanman RB, Meric-Bernstam F. Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer. *Clin Cancer Res* 26(8):1924-1931, 4/2020. e-Pub 12/2019. PMID: 31852833
48. Solomon BJ, Tan L, Lin JJ, Wong SQ, Hollizeck S, Ebata K, Tuch BB, Yoda S, Gainor JF, Sequist LV, Oxnard GR, Gautschi O, Drilon A, Subbiah V, Khoo C, Zhu EY, Nguyen M, Henry D, Condroski KR, Kolakowski GR, Gomez E, Ballard J, Metcalf AT, Blake JF, Dawson SJ, Blosser W, Stancato LF, Brandhuber BJ, Andrews S, Robinson BG, Rothenberg SM. RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies. *J Thorac Oncol* 15(4):541-549, 4/2020. e-Pub 1/2020. PMID: PMC7430178.
49. Dickson D, Johnson J, Bergan R, Owens R, Subbiah V, Kurzrock R. Snapshot: Trial Types in Precision Medicine. *Cell* 181(1):208-208.e1, 4/2020. PMID: 32243791.
50. Subbiah V, Yang D, Velcheti V, Drilon A, Meric-Bernstam F. State-of-the-Art Strategies for Targeting RET-Dependent Cancers. *J Clin Oncol* 38(11):1209-1221, 4/2020. e-Pub 2/2020. PMID: PMC7145587.
51. Groisberg R, Roszik J, Conley AP, Lazar AJ, Portal DE, Hong DS, Naing A, Herzog CE, Somaiah N, Zarzour MA, Patel S, Brown RE, Subbiah V. Genomics, Morphoproteomics, and Treatment Patterns of Patients with Alveolar Soft Part Sarcoma and Response to Multiple Experimental Therapies. *Mol Cancer Ther* 19(5):1165-1172, 5/2020. e-Pub 3/2020. PMID: 32127467.
52. Trigo J, Subbiah V, Besse B, Moreno V, López R, Sala MA, Peters S, Ponce S, Fernández C, Alfaro V, Gómez J, Kahatt C, Zeaiter A, Zaman K, Boni V, Arrondeau J, Martínez M, Delord JP, Awada A, Kristeleit R, Olmedo ME, Wannesson L, Valdivia J, Rubio MJ, Anton A, Sarantopoulos J, Chawla SP, Mosquera-Martinez J, D'Arcangelo M, Santoro A, Villalobos VM, Sands J, Paz-Ares L. Lurbinectedin as second-line treatment for patients with small-cell lung

- cancer: a single-arm, open-label, phase 2 basket trial. *Lancet Oncol* 21(5):645-654, 5/2020. e-Pub 3/2020. PMID: 32224306.
53. Subbiah V, Puzanov I, Blay JY, Chau I, Lockhart AC, Raje NS, Wolf J, Baselga J, Meric-Bernstam F, Roszik J, Diamond EL, Riely GJ, Sherman EJ, Riehl T, Pitcher B, Hyman DM. Pan-Cancer Efficacy of Vemurafenib in BRAFV600-Mutant Non-Melanoma Cancers. *Cancer Discov* 10(5):657-663, 5/2020. e-Pub 2/2020. PMID: PMC7196502.
54. Alhalabi O, Iyer S, Subbiah V. Testing for COVID-19 in patients with cancer. *EClinicalMedicine* 23:100374, 6/2020. e-Pub 5/2020. PMID: PMC7196399
55. Amin HM, Morani AC, Daw NC, Lamhamedi-Cherradi SE, Subbiah V, Menegaz BA, Vishwamitra D, Eskandari G, George B, Benjamin RS, Patel S, Song J, Lazar AJ, Wang WL, Kurzrock R, Pappo A, Anderson PM, Schwartz GK, Araujo D, Cuglievan B, Ratan R, McCall D, Mohiuddin S, Livingston JA, Molina ER, Naing A, Ludwig JA. IGF-1R/mTOR Targeted Therapy for Ewing Sarcoma: A Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive Biomarkers. *Cancers (Basel)* 12(7), 7/2020. e-Pub 7/2020. PMID: PMC7408058.
56. Alhalabi O, Subbiah V. Managing Cancer Care during the COVID-19 Pandemic and Beyond. *Trends Cancer* 6(7):533-535, 7/2020. e-Pub 4/2020. PMID: PMC7184021.
57. Belli C, Anand S, Gainor JF, Penault-Llorca F, Subbiah V, Drilon A, André F, Curigliano G. Progresses Toward Precision Medicine in RET-altered Solid Tumors. *Clin Cancer Res.* e-Pub 7/2020. PMID: 32665298.
58. Sen S, Tanaka R, Khatua S, Zaky W, Janku F, Penas-Prado M, Weathers SP, Behrang A, Roszik J, Subbiah V. Dual inhibition of BRAF and mTOR in BRAF V600E -mutant pediatric, adolescent, and young adult brain tumors. *Cold Spring Harb Mol Case Stud* 6(4), 8/2020. e-Pub 8/2020. PMID: 32843426.
59. Drilon A, Oxnard GR, Tan DSW, Loong HHH, Johnson M, Gainor J, McCoach CE, Gautschi O, Besse B, Cho BC, Peled N, Weiss J, Kim YJ, Ohe Y, Nishio M, Park K, Patel J, Seto T, Sakamoto T, Rosen E, Shah MH, Barlesi F, Cassier PA, Bazhenova L, De Braud F, Garralda E, Velcheti V, Satouchi M, Ohashi K, Pennell NA, Reckamp KL, Dy GK, Wolf J, Solomon B, Falchook G, Ebata K, Nguyen M, Nair B, Zhu EY, Yang L, Huang X, Olek E, Rothenberg SM, Goto K, Subbiah V. Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. *N Engl J Med* 383(9):813-824, 8/2020. PMID: 32846060.

60. Wirth LJ, Sherman E, Robinson B, Solomon B, Kang H, Lorch J, Worden F, Brose M, Patel J, Lebouilleux S, Godbert Y, Barlesi F, Morris JC, Owonikoko TK, Tan DSW, Gautschi O, Weiss J, de la Fouchardière C, Burkard ME, Laskin J, Taylor MH, Kroiss M, Medioni J, Goldman JW, Bauer TM, Levy B, Zhu VW, Lakhani N, Moreno V, Ebata K, Nguyen M, Heirich D, Zhu EY, Huang X, Yang L, Kherani J, Rothenberg SM, Drilon A, Subbiah V, Shah MH, Cabanillas ME. Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. *N Engl J Med* 383(9):825-835, 8/2020. PMID: 32846061.
61. Morani AC, Hanafy AK, Marcal LP, Subbiah V, Le O, Bathala TK, Elsayes KM. Imaging of acute abdomen in cancer patients. *Abdom Radiol (NY)* 45(8):2287-2304, 8/2020. PMID: 31758230.
62. Anand K, Sahu G, Burns E, Ensor A, Ensor J, Pingali SR, Subbiah V, Iyer SP. Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors. *ESMO Open* 5(4), 8/2020. PMCID: PMC7437685.
63. Subbiah V, Erwin WD, Mawlawi O, McCoy A, Wages D, Wheeler C, Gonzalez-Lepera C, Liu H, Macapinlac HA, Meric-Bernstam F, Hong DS, Pant S, Le DB, Santos E, Gonzalez JF, Roszik J, Suzuki T, Subach RA, Madden T, Johansen M, Nomura F, Satoh H, Matsuura T, Kajita M, Nakamura E, Funase Y, Matsushima S, Ravizzini G. Phase 1 Study of P-cadherin-Targeted Radioimmunotherapy with 90Y-FF-21101 Monoclonal Antibody in Solid Tumors. *Clin Cancer Res.* e-Pub 8/2020. PMID: 32816889.
64. Jimenez C, Subbiah V, Stephen B, Ma J, Milton D, Xu M, Zarifa A, Akhmedzhanov FO, Tsimberidou A, Habra MA, Rodon Anher J, Fu S, Naing A. Phase II Clinical Trial of Pembrolizumab in Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas. *Cancers (Basel)* 12(8), 8/2020. e-Pub 8/2020. PMCID: PMC7465458.
65. Subbiah V, Baik C, Kirkwood JM. Clinical Development of BRAF plus MEK Inhibitor Combinations. *Trends Cancer* 6(9):797-810, 9/2020. e-Pub 6/2020. PMID: 32540454.
66. Subbiah V, Lassen U, Élez E, Italiano A, Curigliano G, Javle M, de Braud F, Prager GW, Greil R, Stein A, Fasolo A, Schellens JHM, Wen PY, Viele K, Boran AD, Gasal E, Burgess P, Ilankumaran P, Wainberg ZA. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. *Lancet Oncol* 21(9):1234-1243, 9/2020. e-Pub 8/2020. PMID: 32818466.

67. Pasalic D, McGinnis GJ, Fuller CD, Grossberg AJ, Verma V, Mainwaring W, Miller AB, Lin TA, Jethanandani A, Espinoza AF, Diefenhardt M, Das P, Subbiah V, Subbiah IM, Jagsi R, Garden AS, Fokas E, Rödel C, Thomas CR, Minsky BD, Ludmir EB. Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trials. *Eur J Cancer* 136:176-185, 9/2020. e-Pub 7/2020. PMID: 32702645.
68. Subbiah V, Dumbrava EI, Jiang Y, Thein KZ, Naing A, Hong DS, Fu S, Piha-Paul SA, Tsimberidou AM, Janku F, Meric-Bernstam F, Kurzrock R, Falchook G. Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial. *Exp Hematol Oncol* 9:7, 2020. e-Pub 4/2020. PMCID: PMC7171918.
69. Subbiah V, Lassen U, Élez E, Italiano A, Curigliano G, Javle M, de Braud F, Prager GW, Greil R, Stein A, Fasolo A, Schellens JHM, Wen PY, Viele K, Boran AD, Gasal E, Burgess P, Ilankumaran P, Wainberg ZA. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. *Lancet Oncol* 21(9):1234-1243, 9/2020. e-Pub 8/2020. PMID: 32818466
70. Abi Jaoude J, Kouzy R, El Alam MB, Subbiah V, Taniguchi CM, Ludmir EB, Lin TA. Exclusion of Older Adults in COVID-19 Clinical Trials. *Mayo Clin Proc* 95(10):2293-2294, 10/2020. e-Pub 8/2020. PMCID: PMC7427627.
71. Adashek JJ, Subbiah V, Kurzrock R. From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm. *Trends Cancer*. e-Pub 9/2020. PMID: 33008795
72. Hegde A, Andreev-Drakhlin AY, Roszik J, Huang L, Liu S, Hess K, Cabanillas M, Hu MI, Busaidy NL, Sherman SI, Dadu R, Grubbs EG, Ali SM, Lee J, Elamin YY, Simon GR, Blumenschein GR, Papadimitrakopoulou VA, Hong D, Meric-Bernstam F, Heymach J, Subbiah V. Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies. *ESMO Open* 5(5), 10/2020. PMCID: PMC7590373.
73. Fudio S, Tabernero J, Subbiah V, Chawla SP, Moreno V, Longo F, Lopez R, Anton A, Trigo JM, Shapiro G, Jeong W, Villalobos VM, Lubomirov R, Fernandez-Teruel C, Alfaro V, Boni V. Effect of lurbnectedin on the QTc interval in patients with advanced solid tumors: an exposure-response analysis. *Cancer Chemother Pharmacol*. e-Pub 10/2020. PMID: 33108504.

74. Subbiah V, Paz-Ares L, Besse B, Moreno V, Peters S, Sala MA, López-Vilariño JA, Fernández C, Kahatt C, Alfaro V, Siguero M, Zeaiter A, Zaman K, López R, Ponce S, Boni V, Arrondeau J, Delord JP, Martínez M, Wannesson L, Antón A, Valdivia J, Awada A, Kristeleit R, Olmedo ME, Rubio MJ, Sarantopoulos J, Chawla SP, Mosquera-Martinez J, D' Arcangelo M, Santoro A, Villalobos VM, Sands J, Trigo J. Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment. *Lung Cancer* 150:90-96. e-Pub 10/2020. PMID: 33096421
75. Groisberg R, Subbiah V. Sequencing PEComas: Viewing Unicorns through the Molecular Looking Glass. *Oncology*:1-3. e-Pub 10/2020. PMID: 33049750.
76. Groisberg R, Subbiah V. EZH2 inhibition for epithelioid sarcoma and follicular lymphoma. *Lancet Oncol* 21(11):1388-1390, 11/2020. e-Pub 10/2020. PMID: 33035458.
77. Janku F, Park H, Call SG, Madwani K, Oki Y, Subbiah V, Hong DS, Naing A, Velez-Bravo VM, Barnes TG, Hagemester FB, Falchook GS, Karp DD, Wheler JJ, Piha-Paul SA, Garrido-Laguna I, Shpall EJ, Fayad LE, Neelapu SS, Meric-Bernstam F, Kurzrock R, Fanale MA. Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma. *Clin Cancer Res* 26(21):5579-5587, 11/2020. e-Pub 10/2020. PMID: 33055173
78. Andreev-Drakhlin A, Cabanillas M, Amini B, Subbiah V. Systemic and CNS Activity of Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET-Mutant Medullary Thyroid Cancer With Extensive CNS Metastases. *JCO Precis Oncol* 4, 2020. e-Pub 10/2020. PMCID: PMC7608524.
79. Norris DC, Sen S, Groisberg R, Subbiah V. Patient-Centered, Physician-Investigator Friendly Pragmatic Phase Trial Designs-The 4P Model. *Mayo Clin Proc* 95(11):2566-2568, 11/2020. PMID: 33153645
80. Jozaghi Y, Zafereo M, Williams MD, Gule-Monroe MK, Wang J, Grubbs EG, Vaporciyan A, Hu MI, Busaidy N, Dadu R, Waguespack SG, Subbiah V, Cabanillas M. Neoadjuvant selpercatinib for advanced medullary thyroid cancer. *Head Neck*. e-Pub 11/2020. PMID: 33169506.
81. Subbiah V, Shen T, Terzyan SS, Liu X, Hu X, Patel KP, Hu M, Cabanillas M, Behrang A, Meric-Bernstam F, Vo PTT, Mooers BHM, Wu J. Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations. *Ann Oncol*. e-Pub 11/2020. PMID: 33161056.

82. Hahn AW, Alhalabi O, Msaouel P, Meric-Bernstam F, Naing A, Jonasch E, Piha-Paul S, Hong D, Pant S, Yap T, Campbell E, Le H, Tannir NM, Roszik J, Subbiah V. Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials. *ESMO Open* 5(6), 11/2020. PMID: PMC7684827.
83. Ganeshan D, Kambadakone A, Nikolaidis P, Subbiah V, Subbiah IM, Devine C. Current update on gallbladder carcinoma. *Abdom Radiol (NY)*. e-Pub 1/2021. PMID: 33386907.
84. Tsimberidou AM, Vo HH, Subbiah V, Janku F, Piha-Paul S, Yilmaz B, Gong J, Naqvi MF, Tu SM, Campbell M, Meric-Bernstam F, Naing A. Pembrolizumab in Patients with Advanced Metastatic Germ Cell Tumors. *Oncologist*. e-Pub 1/2021. PMID: 33491277.
85. How JA, Jazaeri A, Westin SN, Sood AK, Ramondetta LM, Xu M, Abonofal A, Karp DD, Subbiah V, Stephen B, Rodon JA, Yang F, Naing A. The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial. *Invest New Drugs*. e-Pub 1/2021. PMID: 33415580
86. Luke JJ, Barlesi F, Chung K, Tolcher AW, Kelly K, Hollebecque A, Le Tourneau C, Subbiah V, Tsai F, Kao S, Cassier PA, Khasraw M, Kindler HL, Fang H, Fan F, Allaire K, Patel M, Ye S, Chao DT, Henner WR, Hayflick JS, McDevitt MA, Fong L. Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors. *J Immunother Cancer* 9(2), 2/2021. PMID: PMC7898862.
87. Hegde A, Jayaprakash P, Couillault CA, Piha-Paul S, Karp D, Rodon J, Pant S, Fu S, Ileana Dumbrava EE, Yap TA, Subbiah V, Bhosale P, Coarfa C, Higgins JP, Williams ET, Wilson TF, Lim J, Meric-Bernstam F, Sumner E, Zain H, Nguyen D, Nguyen LM, Rajapakshe K, Curran MA, Hong DS. A Phase I Dose Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies. *Clin Cancer Res*. e-Pub 3/2021. PMID: 33771853.
88. Desai A, Gainor JF, Hegde A, Schram AM, Curigliano G, Pal S, Liu SV, Halmos B, Groisberg R, Grande E, Dragovich T, Matrana M, Agarwal N, Chawla S, Kato S, Morgan G, Kasi PM, Solomon B, Loong HH, Park H, Choueiri TK, Subbiah IM, Pemmaraju N, Subbiah V, COVID19 and Cancer Clinical Trials Working Group. Author Correction: COVID-19 vaccine guidance for patients with

cancer participating in oncology clinical trials. *Nat Rev Clin Oncol*. e-Pub 3/2021. PMID: PMC7985918

89. Groisberg R, Subbiah V. Combination therapies for Precision Oncology: The Ultimate Whack-A-Mole Game. *Clin Cancer Res*. e-Pub 3/2021. PMID: 33707180
90. Desai A, Gainor JF, Hegde A, Schram AM, Curigliano G, Pal S, Liu SV, Halmos B, Groisberg R, Grande E, Dragovich T, Matrana M, Agarwal N, Chawla S, Kato S, Morgan G, Kasi PM, Solomon B, Loong HH, Park H, Choueiri TK, Subbiah IM, Pemmaraju N, Subbiah V, COVID19 and Cancer Clinical Trials Working Group. COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. *Nat Rev Clin Oncol*. e-Pub 3/2021. PMID: PMC7957448.
91. Addeo A, Passaro A, Malapelle U, Luigi Banna G, Subbiah V, Friedlaender A. Immunotherapy in non-small cell lung cancer harbouring driver mutations. *Cancer Treat Rev* 96:102179. e-Pub 3/2021. PMID: 33798954
92. Alhalabi O, Hahn AW, Msaouel P, Andreev-Drakhlin AY, Meric-Bernstam F, Naing A, Piha-Paul S, Filip J, Pant S, Yap TA, Hong DS, Fu S, Karp D, Campbell E, Le H, Campbell MT, Shah AY, Tannir NM, Siefker-Radtke AO, Gao J, Roszik J, Subbiah V. Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes. *Mol Cancer Res* 19(3):395-402, 3/2021. e-Pub 12/2020. PMID: 33323389.
93. Al-Zubidi N, Gombos DS, Hong DS, Subbiah V, Fu S, Ahnert JR, Piha-Paul SA, Tsimberidou AM, Karp DD, Bernstam FM, Naing A. Overview of Ocular Side Effect of Selinexor. *Oncologist*. e-Pub 3/2021. PMID: 33728727.
94. Huey RW, George GC, Phillips P, White R, Fu S, Janku F, Karp DD, Naing A, Piha-Paul S, Subbiah V, Tsimberidou AM, Pant S, Yap TA, Rodon J, Meric-Bernstam F, Shih YT, Hong DS. Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials. *Oncologist*. e-Pub 3/2021. PMID: 33783054.
95. Yao S, Janku F, Subbiah V, Stewart J, Patel SP, Kaseb A, Westin SN, Naing A, Tsimberidou AM, Hong D, Piha-Paul SA, Shi N, Johnston A, Bomalaski J, Fu S. Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies. *Br J Cancer*. e-Pub 3/2021. PMID: 33674736.
96. Tsimberidou AM, Hong DS, Fu S, Karp DD, Piha-Paul S, Kies MS, Ravi V,

- Subbiah V, Patel SM, Tu SM, Janku F, Heymach J, Johnson A, Cartwright C, Zhao L, Zhang J, Berry DA, Vining DJ, Futreal A, Miller VA, Meric-Bernstam F. Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study. *NPJ Precis Oncol* 5(1):21, 3/2021. e-Pub 3/2021. PMID: PMC7979841.
97. Demetri GD, Luke JJ, Hollebecque A, Powderly J, Spira AI, Subbiah V, Naumovski L, Chen C, Fang H, Lai DW, Yue H, Polepally AR, Purcell JW, Robinson R, Sharma P, Allison JP, Tolcher AW, Villalobos VM. First-in-Human Phase 1 Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors. *Clin Cancer Res.* e-Pub 4/2021. PMID: 33820780.
98. Colen RR, Rolfo C, Ak M, Ayoub M, Ahmed S, Elshafeey N, Mamindla P, Zinn PO, Ng C, Vikram R, Bakas S, Peterson CB, Rodon Ahnert J, Subbiah V, Karp DD, Stephen B, Hajjar J, Naing A. Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers. *J Immunother Cancer* 9(4), 4/2021. PMID: PMC8051405.
99. Thein KZ, Piha-Paul SA, Tsimberidou A, Karp DD, Janku F, Zarifa A, Shah J, Milton DR, Bean S, McQuinn L, Gong J, Colen R, Carter BW, Subbiah V, Ogbonna DC, Pant S, Meric-Bernstam F, Naing A. Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study. *Invest New Drugs.* e-Pub 4/2021. PMID: 33909232
100. Subbiah V, Gainor JF, Oxnard GR, Tan DSW, Owen DH, Cho BC, Loong HHF, McCoach CE, Weiss J, Kim YJ, Bazhenova L, Park K, Daga H, Besse B, Gautschi O, Rolfo C, Zhu EY, Kherani JF, Huang X, Kang S, Drilon A. Intracranial efficacy of selpercatinib in RET fusion-positive non-small cell lung cancers on the LIBRETTO-001 trial. *Clin Cancer Res.* e-Pub 6/2021. PMID: 34088726.
101. Shen T, Hu X, Liu X, Subbiah V, Mooers BHM, Wu J. The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib. *NPJ Precis Oncol* 5(1):48, 6/2021. e-Pub 6/2021. PMID: PMC8184971.
102. Piha-Paul SA, Dumbrava EE, Nair BC, Xiong W, Xu L, Mostorino R, Subbiah V, Tannir N, Fu S, Naing A, Janku F, Karp DD, Patel S, Daw NC, Hong D, Meric-Bernstam F, Zinner R. A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies. *Onco Targets Ther* 14:3037-3049, 2021. e-Pub

103. Subbiah V, Shen T, Tetzlaff M, Weissferdt A, Byers LA, Cascone T, Behrang A, Meric-Bernstam F, Mooers BHM, Rothenberg SM, Ebata K, Wu J. Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer. *Ann Oncol* 32(6):817-819, 6/2021. e-Pub 2/2021. PMCID: PMC8119360.
104. Desai A, Subbiah IM, Subbiah V. Advances in cancer research dissemination through the pandemic and beyond. *Ann Oncol* 32(6):689-693, 6/2021. e-Pub 2/2021. PMID: 33636283.
105. Reddy NK, Subbiah V. Right to Try, expanded access use, Project Facilitate, and clinical trial reform. *Ann Oncol*. e-Pub 6/2021. PMID: 34166758.
106. Abi Jaoude J, Kouzy R, Ghabach M, Patel R, Pasalic D, Ghossain E, Miller AB, Lin TA, Verma V, Fuller CD, Subbiah V, Minsky BD, Ludmir EB, Taniguchi CM. Food and Drug Administration approvals in phase 3 Cancer clinical trials. *BMC Cancer* 21(1):695, 6/2021. e-Pub 6/2021. PMCID: PMC8196526
107. Gainor JF, Curigliano G, Kim DW, Lee DH, Besse B, Baik CS, Doebele RC, Cassier PA, Lopes G, Tan DSW, Garralda E, Paz-Ares LG, Cho BC, Gadgeel SM, Thomas M, Liu SV, Taylor MH, Mansfield AS, Zhu VW, Clifford C, Zhang H, Palmer M, Green J, Turner CD, Subbiah V. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. *Lancet Oncol* 22(7):959-969, 7/2021. e-Pub 6/2021. PMID: 34118197.
-